Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study.

BACKGROUND

Prospectively and systematically collected real-world data on vedolizumab are scarce. We aimed to assess the long-term clinical effectiveness of vedolizumab in inflammatory bowel disease (IBD).

METHODS

This study was a prospective, observational, multicentre study. Overall, 286 patients with active IBD were included (Crohn's disease,

RESULTS

At baseline, 88% of the patients were exposed to anti-TNF and 41% of the patients with Crohn's disease had undergone ⩾1 surgical resection. At week 12, clinical response was 27% and remission 47% in Crohn's disease; corresponding figures in ulcerative colitis were 52% and 34%. Clinical response, remission and corticosteroid-free remission at week 52 were 22%, 41% and 40% in Crohn's disease and 49%, 47% and 46% in ulcerative colitis, respectively. A statistically significant decrease in median faecal-calprotectin and C-reactive protein was observed at 12 and 52 weeks in patients with Crohn's disease and ulcerative colitis. The HRQoL measures Short Health Scale and EuroQol 5-Dimensions improved in both Crohn's disease and ulcerative colitis patients (

CONCLUSION

Vedolizumab proved effective for the treatment of refractory IBD in clinical practice.

Informations de copyright

© The Author(s), 2021.

Déclaration de conflit d'intérêts

Conflict of interest statement: CE has served as a speaker, a consultant and an advisory board member for Takeda, Janssen Cilag, Pfizer, Abbvie, and has received research funding from the Regional Agreement on Medical Training and Clinical Research between Region Örebro County and Örebro University: ALF. SR has served as a speaker for Takeda and has received research funding from the research committee in Region Örebro County and the Regional Agreement on Medical Training and Clinical Research between Region Örebro County and Örebro University: ALF. OG has served as a speaker, a consultant and an advisory board member for Ferring, Janssen, Pfizer and Takeda. SA has served as a speaker, consultant or advisory board member: AbbVie, Janssen, Takeda, Tillotts Pharma, Vifor Pharma. EH has served as a speaker, consultant or advisory board member: Abbvie, Gilead, Janssen, Pfizer and Takeda. JM has served as a speaker, consultant or advisory board member: AbbVie, Bristol-Myers Squibb, Ferring, Hospira, Janssen, MSD, Otsuka, Pfizer, Sandoz, Svar, Takeda, Tillotts and UCB Pharma, and has received grant support from AbbVie, Ferring, Pfizer and Takeda. JG has served as a speaker and consultant: Abbvie, Ferring, Tillotts Pharma, Takeda. CM is an employee of Takeda. HS has served as a speaker, consultant or advisory board member: Abbvie, Ferring, Gilead, Janssen, Pfizer, Takeda and Tillotts Pharma. DB has served as a speaker, consultant or advisory board member: Ferring, Janssen, Pfizer and Takeda. HH has served as a speaker, consultant or advisory board member: AbbVie, Janssen, Pfizer, Takeda, Tillotts Pharma, Vifor Pharma, and received grant support from Ferring and Tillotts Pharma. JH has served as a speaker, consultant or advisory board member: AbbVie, Aqilion, Celgene, Celltrion, Dr Falk Pharma and the Falk Foundation, Ferring, Gilead, Index Pharma, Janssen, Lincs, MSD, Novartis, Olink Proteomics, Pfizer, Prometheus Laboratories Inc., Sandoz, Shire, Takeda, Thermo Fisher Scientific, Tillotts Pharma, Vifor Pharma, and received grant support from Janssen, MSD and Takeda. VL, RU, PK, CS, JD, MS and DÖ have no conflicts of interest.